Why is 3D Medicines stock surging today?
3D Medicines Inc.'s stock price spiked 14.2% to HK$2.85 on Wednesday following a positive announcement from its U.S. partner, SELLAS Life Sciences Group. The biotech company's collaboration with SELLAS showcased promising results from the Phase III REGAL trial of their cancer vaccine, 3D189. The pivotal trial demonstrated that 3D189 significantly reduced the risk of death by 41% compared to standard treatment options, with patients experiencing a median overall survival of 24.0 months compared to 14.7 months in the control group.
These impressive outcomes, which met pre-specified primary efficacy endpoints, have generated substantial optimism in the market. Moreover, SELLAS has expressed intentions to pursue an accelerated approval pathway with the U.S. Food and Drug Administration, likely submitting a Biologics License Application in the first half of 2027.
For 3D Medicines, securing a successful regulatory approval in the United States would not only validate the commercial potential of their asset but also bolster their prospects for obtaining similar approvals in Greater China. Despite the positive news, the broader Hong Kong market remained cautious, with the Hang Seng Index experiencing a slight decline of approximately 1% on the same trading day.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.